Silo Pharma Inc. (SILO) - Koefisien utang jangka dawa marang modal

Silo Pharma, Inc. (SILO) is a biopharmaceutical startup that outsources production and testing to third-party contractors, as evidenced by the price action snapshot on GURU.Markets, where the metric stands at 0.00. The company generates revenue by developing nasal treatments for dementia and PTSD, relying on insurance company payouts. Additionally, the business leverages the prospects of fibromyalgia treatment, anticipating a surge in demand following FDA certification.

The ratio is calculated as the proportion of liabilities with a maturity exceeding one year to the company's total capital. This metric determines the degree of financial leverage and the stability of the balance sheet structure in the face of long-term risks. For Silo Pharma, Inc. (SILO), which is advancing innovative neurological developments, a low debt load confirms investor confidence in the clinical phases. The history of the long-term debt-to-equity ratio reflects the balance between borrowed financing and the ethical stability of the brand.